Claritev Corporation
NYSE:CTEVMedical - Healthcare Information Services
+$0.42 today
- Market cap
- $380.77M
- Beta
- 0.77
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$17.16
Volume 0.31M
Average 0.14M
CTEV Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Claritev CorporationNYSE: CTEV
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $111.65M rose 0.1% year over year, behind the +1.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.1% from the prior quarter. Over 3 fiscal years it compounded at +2.3% a year.
Context
- Depreciation & amortization amounted to 46.1% of revenue in FY2025, down 0.8 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +0.1% toward the trailing-twelve-month pace of +1.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 445.43M USD
- Year-over-year change
- +2.1%
- 4-year CAGR
- +1.2%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 445.43M | +2.1% |
| FY2024 | 2024-12-31 | 436.44M | +2.5% |
| FY2023 | 2023-12-31 | 425.79M | +2.4% |
| FY2022 | 2022-12-31 | 415.66M | -2.0% |
| FY2021 | 2021-12-31 | 424.32M | — |
Depreciation & Amortization vs competitors
How CTEV compares with its peers on the latest reported figures
- CTEV's LTM Mar 2026 depreciation & amortization of $448.02M is the largest of the 11 companies compared; the peer median is $10.21M.
- Its year-over-year change of +1.9% is the 5th highest of 11, against a peer median of -5.7%.
- Depreciation & amortization amounts to 45.8% of revenue for CTEV, versus a peer median of 3.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
CTEVClaritev Corporation | LTM Mar 2026 | $448.02M | +1.9% | +2.3% | 45.8% |
| LTM Mar 2026 | $153.07M | +3.8% | +8.7% | 9.3% | |
| LTM Mar 2026 | $90.34M | -5.7% | -5.5% | 15.5% | |
| LTM Mar 2026 | $82.56M | +10.8% | +16.3% | 10.5% | |
| LTM Mar 2026 | $24.21M | -79.4% | +22.2% | 1.3% | |
| LTM Mar 2026 | $11.5M | -33.5% | -6.6% | — | |
| LTM Sep 2026 | $8.91M | +19.5% | +19.1% | 3.3% | |
| LTM Mar 2026 | $2.76M | -127.4% | -55.7% | 1.3% | |
| LTM Mar 2026 | $1.43M | +81.6% | +20.2% | 1.7% | |
| LTM Mar 2026 | $696K | -5.6% | +0.7% | 0.2% | |
| LTM Jun 2026 | $379K | -11.0% | +42.8% | 19.9% | |
| Peer median (excluding CTEV) | $10.21M | -5.7% | +12.5% | 3.3% | |
Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 102.08M | (572.91M) | (91.7M) | (1.65B) | (284.28M) |
| Depreciation & Amortization | 424.32M | 415.66M | 425.79M | 436.44M | 445.43M |
| Deferred Income Tax | (81.93M) | (114.38M) | (114.06M) | (198.01M) | (128.51M) |
| Stock-Based Compensation | 18.01M | 16.74M | 18.02M | 26.65M | 27.82M |
| Change in Working Capital | (46.68M) | 55.34M | (21.91M) | (13.67M) | (28.87M) |
| Accounts Receivables | (33.83M) | 21M | 4.4M | (13.2M) | (26.57M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 7.71M | 34.35M | 5.58M | 42.22M | (25.86M) |
| Other Working Capital | (12.85M) | 34.34M | (26.31M) | (42.69M) | 23.57M |
| Other Non-Cash Items | (93.04M) | 571.92M | (44.42M) | 1.5B | 85.73M |
| Operating Cash Flow | 404.69M | 372.36M | 171.72M | 107.62M | 117.32M |
| Capital Expenditures | (84.59M) | (89.74M) | (108.85M) | (118.12M) | (129.6M) |
| Acquisitions (Net) | (149.43M) | 0 | (140.94M) | 0 | 0 |
| Purchases of Investments | 0 | (15M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 289K | 0 | 0 | 16M |
| Other Investing Activities | 5.64M | 0 | 0 | 0 | (7.42M) |
| Investing Cash Flow | (228.38M) | (104.45M) | (249.79M) | (118.12M) | (121.02M) |
| Debt Repayment | (10.9M) | (13.28M) | (165.82M) | (28.07M) | 4.72M |
| Common Stock Issued | 0 | 0 | 508K | 0 | 1.74M |
| Common Stock Repurchased | (103.79M) | (100M) | (15.22M) | (10.37M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.79M) | (2.46M) | (465K) | (2.88M) | (4.1M) |
| Financing Cash Flow | (114.68M) | (115.74M) | (180.99M) | (41.32M) | 2.36M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 61.62M | 152.18M | (259.07M) | (51.82M) | (1.33M) |
| Free Cash Flow | 320.1M | 282.63M | 62.87M | (10.51M) | (12.28M) |
Claritev Corporation
NYSE:CTEV
Intrinsic Alpha fair value
Locked
Current Price
$22.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.